We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IART icon
26
Integra LifeSciences
IART
$1.5B
$52.2M 0.91%
1,473,090
+344,091
+30% +$13.8M
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$45.4M 0.79%
1,411,000
+788,888
+127% +$29.3M
GPCR icon
28
Structure Therapeutics
GPCR
$3.45B
$44.3M 0.77%
1,033,680
+210,867
+26% +$8.89M
IRON icon
29
Disc Medicine
IRON
$2.91B
$41.4M 0.72%
665,535
+201,243
+43% +$13M
ALHC icon
30
Alignment Healthcare
ALHC
$4.26B
$41M 0.71%
8,270,697
+4,781,889
+137% +$30.6M
VKTX icon
31
Viking Therapeutics
VKTX
$4.31B
$38M 0.66%
463,501
-815,499
-64% -$36.3M
KYTX icon
32
Kyverna Therapeutics
KYTX
$453M
$36.3M 0.63%
+1,462,337
New +$40.8M
EMBC icon
33
Embecta
EMBC
$193M
$36.2M 0.63%
2,726,135
+1,341,296
+97% +$20.8M
CATX icon
34
Perspective Therapeutics
CATX
$341M
$33.5M 0.58%
+2,817,764
New +$24M
SLDB icon
35
Solid Biosciences
SLDB
$858M
$30.1M 0.52%
+2,260,398
New +$21.2M
DAWN
36
DELISTED
Day One Biopharmaceuticals
DAWN
$29.2M 0.51%
1,765,312
+4,134
+0.2% +$61.9K
CNMD icon
37
CONMED
CNMD
$1.3B
$27.1M 0.47%
338,165
+335,609
+13,130% +$29.9M
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.36B
$25.4M 0.44%
4,995,000
+455,475
+10% +$2.56M
INMD icon
39
InMode
INMD
$889M
$25.2M 0.44%
+1,166,704
New +$26.1M
ACCD
40
DELISTED
Accolade Inc
ACCD
$25M 0.43%
+2,382,102
New +$27.1M
PHVS icon
41
Pharvaris
PHVS
$2.44B
$24.5M 0.43%
1,061,592
+249,356
+31% +$6.62M
AUTL
42
Autolus Therapeutics
AUTL
$383M
$23.2M 0.4%
+3,639,000
New +$22.7M
APGE icon
43
Apogee Therapeutics
APGE
$10.1B
$21.9M 0.38%
+329,000
New +$14.4M
CABA icon
44
Cabaletta Bio
CABA
$461M
$21.5M 0.37%
1,258,650
-749,079
-37% -$16.1M
DCGO icon
45
DocGo
DCGO
$64.3M
$20.6M 0.36%
5,104,387
-215,752
-4% -$814K
CSTL icon
46
Castle Biosciences
CSTL
$733M
$20.6M 0.36%
928,017
-37,411
-4% -$814K
PRLD icon
47
Prelude Therapeutics
PRLD
$335M
$19.6M 0.34%
4,133,000
– –
VTYX
48
DELISTED
Ventyx Biosciences
VTYX
$19.5M 0.34%
+3,542,000
New +$16.2M
CGEM icon
49
Cullinan Oncology
CGEM
$1.09B
$19.4M 0.34%
+1,138,531
New +$17.6M
PODD icon
50
Insulet
PODD
$11.4B
$18.9M 0.33%
110,061
-68,859
-38% -$12.8M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.